Login to Your Account

Clinic Roundup

Thursday, February 16, 2012
• Redhill Biopharma Ltd., of Tel Aviv, Israel, said it started a trial of THB-102 for the prevention of nausea and vomiting in cancer patients. The bioequivalence study is designed to test the pharmacokinetic similarity between the company's once-daily, controlled-release tablet formulation of ondansetron and the market-leading anti-emetic, Zofran (ondansetron, GlaxoSmithKline plc), which must be administered several times per day. The drug was developed using technology from Bothell, Wash.-based Scolr Pharma Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription